Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors
Autore:
Patel, SD; Moskalenko, M; Tian, T; Smith, D; McGuinness, R; Chen, LL; Winslow, GA; Kashmiri, S; Schlom, J; Stanners, CP; Finer, MH; McArthur, JG;
Indirizzi:
Cell Genesys Inc, Dept Preclin Biol & Immunol, Foster City, CA 94404 USA Cell Genesys Inc Foster City CA USA 94404 unol, Foster City, CA 94404 USA NCI, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892NCI, Bethesda, MD 20892 USA McGill Canc Ctr, Dept Biochem, Montreal, PQ, Canada McGill Canc Ctr Montreal PQ Canada r, Dept Biochem, Montreal, PQ, Canada McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada McGill Univ Montreal PQ Canada H3G 1Y6 Canc, Montreal, PQ H3G 1Y6, Canada
Titolo Testata:
CANCER GENE THERAPY
fascicolo: 8, volume: 7, anno: 2000,
pagine: 1127 - 1134
SICI:
0929-1903(200008)7:8<1127:TKOHTO>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; CARCINOEMBRYONIC ANTIGEN; ADOPTIVE TRANSFER; MUTATION-RATE; TYPE-1; LYMPHOCYTES; INFECTION; EVOLUTION; GENE;
Keywords:
chimeric immune receptors; bispecific immune receptors; gene therapy; T-cell receptors; immunotherapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: McArthur, JG Cell Genesys Inc, Dept Preclin Biol & Immunol, 342 Lakeside Dr, Foster City, CA 94404 USA Cell Genesys Inc 342 Lakeside Dr Foster City CA USA 94404 USA
Citazione:
S.D. Patel et al., "T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors", CANC GENE T, 7(8), 2000, pp. 1127-1134

Abstract

We have previously described several novel chimeric immune receptors (CIRs) that redirect human T cells to kill malignant or HIV-infected cells. These CIRs comprise a cancer- or virus-specific ligand or single-chain antibodyfused to the signaling domain of the T-ccll receptor CD3-zeta subunit. Binding of the ligand- or antibody-based CIR to the target antigen (Ag) triggers T-cell-mediated cytolysis of the tumor- or virus-infected cell independent of target cell major histocompatibility complex class I expression. A new type of CIR was developed to mediate the lysis of cells that expressed one or more distinct viral or tumor Ags; three bispecific CIRs (BCIRs) were generated that recognized the carcinoembryonic Ag (CEA) and TAG-72 tumor Agsor, alternatively, distinct epitopes in the HIV envelope (HIVenv). T cellsexpressing the antitumoral Ag BCIR lysed both CEA- and TAG-72-expressing targets and did not kill Ag-negative targets or target cells Expressing other members of the CEA family. Similarly, T cells expressing the anti-HIVenv BCIR lysed target cells expressing both the wild-type HIVenv and a mutant HIVenv that lacked the epitopes recognized by the monospecific CIRs. This approach permits the generation of T cells with a broader spectrum of activity capable of killing virus-infected cells and malignant cells and reduces the potential of progression of disease due to Ag loss variants.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 13:34:00